ABSTRACT. Genetic factors have been shown to play a role in the development of head and neck cancers (HNCs). However, studies investigating the association between the TP53 Arg72Pro polymorphism and HNCs susceptibility have yielded conflicting results. Hence, we performed a meta-analysis of all eligible studies (up to January 1, 2012) to derive a more precise estimation of this association in order to increase understanding of the possible risk factors of HNCs. Twenty-seven casecontrol studies involving 3966 cases and 4387 controls were included in our analysis. Overall, no evidence of association was observed between the TP53 Arg72Pro single nucleotide polymorphism (SNP) and the risk of effects across different subtypes of HNCs. For example, there was a lack of association of this polymorphism with oral cavity cancer, whereas a significant association with nasopharyngeal cancer was observed. Results of this meta-analysis suggest that the TP53 Arg72Pro polymorphism might have different effects on the risk of various subtypes of HNCs.
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INTRODUCTION
Head and neck carcinomas (HNCs), including cancers of the oral cavity, pharynx, and larynx, represent the sixth most frequent cancer and the seventh leading cause of cancer-related deaths in the world. There are approximately 540,000 new cases and 271,000 deaths worldwide that are associated with HNCs annually (Parkin et al., 1999) . Development of HNCs is a multifactorial process that is associated with a variety of risk factors. Major risk factors include tobacco smoking, alcohol consumption, and betel-quid chewing. Genetic factors have also been shown to play roles in the development of HNCs (Hiyama et al., 2002; Yokoyama and Omori, 2005) .
As a major regulator of the cellular response to stress, TP53 serves as a tumor suppressor by inducing cell cycle arrest or apoptosis. Indeed, the TP53 gene is frequently mutated in various types of human cancers, including HNCs (Hiyama et al., 2004; Karsai et al., 2007) . Besides mutations, polymorphisms of TP53 have also been reported as possible risk factors for a number of tumors. A common single nucleotide polymorphism (SNP) at codon 72 of TP53 (Pro72Arg, rs1042522) results in two protein forms with different biological and biochemical properties (Thomas et al., 1999) . In particular, the Arg72 variant induces markedly better apoptosis compared to the Pro72 variant, and these two functionally distinct polymorphic variants of TP53 may influence cancer risk or treatment (Dumont et al., 2003) .
The association between the TP53 Arg72Pro polymorphism and HNCs has received considerable attention. However, the results are conflicting and inconclusive (Yung et al., 1997; Nagpal et al., 2002; Hadhri-Guiga et al., 2007) , which may be partially due to differences among the populations studied, as well as particular methodological and study design features. Hence, we performed a meta-analysis of all eligible studies to derive a more precise estimation of the association, which may help to clarify the possible influence of this SNP on the risk of HNCs.
MATERIAL AND METHODS

Identification and eligibility of relevant studies
We conducted a literature search of the PubMed database and the Chinese Biomedical Literature Database (CBM) using the following key words and subject terms: "p53", "TP53", "codon 72", "polymorphism", "oral cancer", "laryngeal cancer", "nasopharyngeal carcinoma", "cancers of the pharynx and larynx", "head and neck squamous cell carcinoma", and "head and neck carcinoma", along with their combinations. References of the retrieved publications (up to January 1, 2012) were also screened. The language of publication was restricted to English or Chinese, and only research articles were included. If an article reported results of separate studies, each study was treated as a separate comparison in our meta-analysis.
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Inclusion and exclusion criteria
The following inclusion criteria were used in literature selection for the meta-analysis: a) published in peer-reviewed journals, b) focused on TP53 Arg72Pro polymorphism and risk of HNCs, and c) contained genotype frequency data. The major exclusion criteria were: a) not case-control studies, b) control population included malignant tumor patients, and c) duplication of a previous publication.
Data extraction
Two investigators (W.H. Ren and D.K. Jiang) reviewed and extracted information from all eligible publications independently according to the inclusion and exclusion criteria listed above. Disagreements were worked out by discussion between the two reviewers. The following characteristics were collected from each study: first author's surname, year of publication, country of origin, ethnicity (categorized as Asian, Caucasian, and Other), source of case and control groups, specimens used for assessment of the TP53 Arg72Pro genotypes, tumor subtype (oral cancer, nasopharyngeal cancer, pharyngeal cancer, laryngeal cancer, and oropharyngeal cancer), total number of cases and controls, and number of cases and controls with the Arg/Arg, Arg/Pro, and Pro/Pro genotypes, respectively.
Quality score assessment
The quality of the studies included was also independently assessed by the same two reviewers according to the predefined scale for quality assessment (Table 1), which was described previously (Jiang et al., 2011) . Briefly, these scores were based on both traditional epidemiological considerations and cancer genetic issues. Any disagreement was resolved by discussion between the two reviewers. Scores ranged from 0 (worst) to 15 (best). Reports with scores below 10 were classified as "low quality", and those scoring 10 and above were classified as "high quality".
Statistical analysis
We first assessed Hardy-Weinberg equilibrium (HWE) in each study using goodnessof-fit tests (chi-squared or Fisher's exact test) only in control groups. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the strength of association between the TP53 Arg72Pro polymorphism and risk of overall and subtypes of HNCs. The pooled ORs were estimated according to the random-effects model (the DerSimonian and Laird model) for the codominant model (homozygote comparison: Arg/Arg vs Pro/Pro; heterozygote comparison: Arg/Pro vs Pro/Pro), dominant model (Arg/Arg+Arg/Pro vs Pro/Pro), and recessive model (Arg/Arg vs Arg/Pro+Pro/Pro), respectively. Stratified analyses were also performed by ethnicity (Caucasian, Asian, and Other) and quality score of studies (<10 and ≥10). A chi-squaredbased Q-test was performed to evaluate the between-study heterogeneity. One-way sensitivity analyses were performed to assess the stability of the meta-analysis results. The potential publication bias was estimated using the Egger linear regression test and by visual inspection of the funnel plot. P < 0.05 was considered to be statistically significant. All statistical tests were preformed with the STATA version 10.0 software (Stata Corporation, College Station, TX, USA). 
RESULTS
Literature search, screening, and data collection
To perform the meta-analysis, we first conducted a literature search (the selection process is shown in Figure S1 ).
Ultimately, 29 studies involving the association of the TP53 Arg72Pro polymorphism with susceptibility to HNCs were collected. However, one of the studies (Brant et al., 2007) lacked genotype data of control groups, and was therefore excluded from the analysis. Moreover, five of the remaining 28 studies (Shen et al., 2002; Lu et al., 2007; Ji et al., 2008; Chen et al., 2007 were carried out in the same research group. Of these five studies, Chen et al. (2007) included cases of all different HNCs subtypes, and contained the most cases. Therefore, this study, but not the other four, was included in the evaluation of overall HNCs in our metaanalysis. However, the genotype data of the TP53 Arg72Pro SNP in different subtypes of HNCs were not provided in this report (Chen et al., 2007) or in that of Lu et al. (2007) . Hence, we chose the other three studies (Shen et al., 2002; Ji et al., 2008; Chen et al., 2008) in the meta-analysis of specific HNCs subtypes, excluding the data from Chen et al. (2007) and Lu et al. (2007) . Shen et al. (2002) analyzed oral, pharyngeal, and laryngeal cancer specifically, whereas Ji et al. (2008) and Chen et al. (2008) studied oropharyngeal cancer as well as oral cancer. Overall, a total of 27 studies consisting of 3966 HNCs cases and 4387 controls were included in our meta-analysis (Yung et al., 1997; Golovleva et al., 1997; McWilliams et al., 2000; Hamel et al., 2000; Summersgill et al., 2000; Tandle et al., 2001; Sourvinos et al., 2001; Nagpal et al., 2002; Shen et al., 2002; Tsai et al., 2002; Tiwawech et al., 2003; Kietthubthew et al., 2003; Katiyar et al., 2003; Scheckenbach et al., 2004; Cortezzi et al., 2004; Hsieh et al., 2005; Sousa et al., 2006; Twu et al., 2006; Hadhri-Guiga et al., 2007; Perrone et al., 2007; Kuroda et al., 2007; Ji et al., 2008; Chen et al., 2007 Chen et al., , 2008 Lin et al., 2008; Tu et al., 2008; Misra et al., 2009) (Table 2 ). The genotype distribution of the TP53 Arg72Pro polymorphism is summarized in Table 3 . Table 3 . Distribution of TP53 Arg72Pro genotypes among HNC cases and controls included in the meta-analysis. HWE = Hardy-Weinberg equilibrium.
Quality assessment of the literature and data analysis
We also conducted a quality assessment for all studies as described above. Sixteen of the 27 (59%) publications included in this analysis were considered to be of high quality. Furthermore, deviations from HWE were tested from the genotype distribution of TP53 Arg72Pro in all control groups, and the results are shown in Table 3 . The distribution of TP53 Arg72Pro genotypes deviated from HWE in two studies (Tandle et al., 2001; Kietthubthew et al., 2003) .
Meta-analysis results
We first conducted a meta-analysis on all HNCs. The results showed no significant correlation between the risk of HNCs and the TP53 Arg72Pro SNP in any genetic model (homozygous comparison: OR = 0.83, 95%CI= 0.65-1.06; heterozygotes compared: OR = 0.88, 95%CI= 0.70-1.10; dominant model: OR = 0.87, 95%CI= 0.70-1.09; recessive model: OR = 0.95, 95%CI= 0.82-1.11; Table 4 ). However, the Q-test indicated heterogeneity in all models (Table 4) .
In order to determine the cause of the heterogeneity and to obtain accurate results, we conducted a stratified analysis according to ethnic groups as well as the quality score of studies. A similar conclusion was reached in all genetic models, except that a strong correlation between the risk of HNCs and the TP53 Arg72Pro SNP was revealed in the Others group under the homozygous comparison, the heterozygous comparison, and the dominant models (P < 0.05, Table 4 ). Random effect model was used when P value for heterogeneity test < 0.1; otherwise, fixed effect model was used. Table 4 . Meta-analysis results on TP53 Arg72Pro polymorphism and the risk of overall head and neck carcinoma.
Next, we analyzed the correlation of the TP53 Arg72Pro SNP with the risk of different HNC subtypes. Overall, TP53 genotypes showed no significant correlation to oral, oropharyngeal, laryngeal, or mixed cancers under all genetic models (Table 5) . However, a strong correlation was found between TP53 genotypes and nasopharyngeal cancer with the homozygous comparison (OR = 0.47, 95%CI = 0.32-0.68), the heterozygous (OR = 0.53, 95%CI = 0.037-0.75), and the dominant model (OR = 0.51, 95%CI = 0.37-071) (Table 5) .
Furthermore, we carried out stratified analysis according to ethnic groups as well as quality score of the studies in various HNC subtypes. It should be noted that in order to accurately interpret the results of statistical analyses, a particular HNC subtype was chosen for analysis only when three or more independent studies addressed it. Therefore, we were only able to analyze the associations with oral and nasopharyngeal cancers in the stratified analysis. No correlation was identified between the susceptibility of oral cancer and the TP53 Arg72Pro SNP in all subgroups under all genetic models. However, analysis of high-quality publications only indicated that the susceptibility of nasopharyngeal cancer was significantly correlated with the TP53 Arg72Pro SNP (Table 5) .
Assessment of publication bias
We also assessed the publication bias using funnel plots, which showed a pattern close to symmetric, indicating no publication bias ( Figure 1 shows the funnel plot of overall Arg/ Arg vs Pro/Pro). In addition, the Egger test was used to quantitatively evaluate the funnel plot symmetry, further revealing no publication bias (homozygous comparison, P = 0.487; heterozygous comparison, P = 0.235; dominant model, P = 0.364; recessive model, P = 0.816). 
DISCUSSION
Reasonable and rigorous experimental designs are essential for correlation studies between genetic polymorphisms and cancer risk. However, the analytical methods used in the studies included in this meta-analysis also have limitations. For example, in some studies, the source, as well as selection criteria of the control and case samples, was not evident (Hamel et al., 2000; Shen et al., 2002; Scheckenbach et al., 2004) , which will cause deviations in the results. In other studies, DNA extracted from tumor tissue samples was used for TP53 genotyping (Yung et al., 1997; Perrone et al., 2007) , which is known to result in frequent loss of heterozygosity, and may result in false-positive conclusions. We also found deviations in HWE of the control samples in two studies (Tandle et al., 2001; Kietthubthew et al., 2003) . In addition, some of the studies were carried out with very small sample sizes, which will result in insufficient statistical power, and may cause observed differences by chance. Because of all the problems mentioned above, we also conducted a quality assessment on the literature used in our meta-analysis.
No evidence of an association between the risk of HNCs and the TP53 Arg72Pro SNP was observed in Asian and Caucasian populations, whereas a significant association was observed in the Others group. In addition, significant correlations between risk of nasopharyngeal cancer and the TP53 Arg72Pro SNP were observed in the homozygous comparison, heterozygous comparison, and the dominant model in Caucasians, whereas in Asians, this correlation was only found to be significant in the homozygous comparison model. This result suggests that TP53 polymorphisms might play different roles in different HNC sites, which would contribute to the discrepancy observed among different studies. Moreover, although the exact mechanism for this ethnic difference is yet to be established, several factors may account for it. First, different genetic backgrounds of the populations may cause functional differences in a particular polymorphism. Second, environmental differences may result in different susceptibilities of a particular SNP in different populations. Finally, random factors, such as selection bias, different matching criteria, adjustments in statistical analyses, misclassifications of disease status or genotyping, and publication bias may all be involved. Therefore, additional studies are warranted to further validate ethnic difference in the effect of this polymorphism on all types of HNC risks.
Recently, Francisco et al. (2011) conducted a meta-analysis to investigate the association between the TP53 Arg72Pro polymorphism and risk of all cancers, including HNCs. In addition, one recent meta-analysis also detected no evidence of a significant association between the TP53 Arg72Pro polymorphism and risk of oral cancer (Zhuo et al., 2009b) , and another meta-analysis observed a significant association of the TP53 Arg72Pro polymorphism with nasopharyngeal cancer susceptibility (Zhuo et al., 2009a) , which are all consistent with our results. Nevertheless, three more eligible articles related to oral cancer (Tandle et al., 2001; Kietthubthew et al., 2003; Misra et al., 2009 ) and one more eligible article related to nasopharyngeal cancer (Golovleva et al., 1997) were included in our meta-analysis that were not included in the two previous meta-analyses.
This meta-analysis also has some limitations. First, reports written in languages other than English or Chinese, or those written in English or Chinese but have not been published, were not incorporated in this meta-analysis. Second, most studies investigating the association of the TP53 Arg72Pro SNP with HNCs susceptibility mainly involve Asian and Caucasian populations. Thus, expansion of the population scope in future correlation
